HSIE Results Daily 30th Apr'26: Bajaj Finance, Indian Bank, and more Companies Result Analysis

HSIE Results Daily 30th Apr’26: Bajaj Finance, Indian Bank, Federal Bank, Star Health and Allied Insurance, Piramal Pharma

Bajaj Finance

Bajaj Finance delivered in-line results, supported by strong AUM growth of 22.4% YoY, marginal net interest margin improvement, and lower credit costs. Asset quality metrics improved sequentially, with better vintage performance expected to aid FY27 credit costs. The ongoing FINAI transformation remains on track, aimed at improving productivity and operating efficiency amid a diversified lending franchise.

Indian Bank

Indian Bank posted a steady Q4FY26 performance, driven by healthy credit and deposit growth, particularly across retail, gold, and MSME segments. CASA ratios remained stable, supporting funding strength. Credit costs rose due to higher MSME and agriculture slippages and additional provisions. Business momentum remains strong, though sensitivity to macro uncertainty persists given segmental exposure.

Federal Bank

Federal Bank reported a modest miss, excluding a one‑off tax benefit, with softer NII offset by strong other income. Deposit growth remained healthy, led by improving CASA balances. Asset quality stayed stable, while loan growth continued in medium‑yield segments. Rising stress in core MSME books warrants monitoring, though balance‑sheet strength and capital buffers remain supportive.

Star Health and Allied Insurance

Star Health reported lower‑than‑expected premium growth, with profit supported by a sharp improvement in loss ratios during the quarter. Full‑year loss ratios have reset to a lower baseline, though structural challenges persist in underwriting, pricing, and distribution. Investments in customer experience continue to improve claims settlement efficiency, aiding medium‑term operational stability.

Piramal Pharma

Piramal Pharma’s margins improved sequentially despite YoY EBITDA decline, reflecting operating leverage amid flat revenue growth. CDMO revenues were impacted by product supply gaps, though recovery is expected with improving global funding and project inflows. Expansion investments across sterile injectables and differentiated capabilities continue, while branded and inhalation segments are expected to sustain steady growth momentum.

Download the Full Report: Click Here